BioSpace News Archive

GN Hearing, the global leader in hearing aid innovation, announces the expansion of the popular ReSound OMNIA family, providing more options to address the biggest unmet need for people with hearing loss: hearing speech in noisy environments.

EVONETIX LTD, the synthetic biology company bringing semiconductor technology to DNA synthesis, announced it has completed a USD $24 million financing round, extending its total series B funding to over USD $54 million.

Encision Inc., a medical device company owning patented Active Electrode Monitoring Technology that prevents dangerous radiant energy burns in minimally invasive surgery, announced financial results for its fiscal year 2023 third quarter that ended December 31, 2022.

Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal 2023, which ended December 31, 2022, are available on its Investor Relations website.

Centogene N.V. today announced its partnering conference schedule for February 2023, with a focus on rare and genetic diseases in the lead up to Rare Disease Day (RDD) on February 28th.

Freudenberg Medical, a global contract design and manufacturing provider to the medical device and pharmaceutical industry, has added custom silicone extrusion and tube processing to its new cleanroom manufacturing operation in Beverly, Massachusetts.

NextCure, Inc. today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15th at 1:40 pm ET.

First Wave BioPharma, Inc. today announced that on February 6, 2023, the Company received formal notice from the Nasdaq Hearing Panel (the “Panel”) indicating that First Wave BioPharma has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and advised that the Panel’s oversight process of the Company is now closed.

Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced that an Arch scientist at the University of Calgary was awarded a Canadian Institute of Health Resources (CIHR) Project Grant worth $1,109,250 to further study the role of dipeptidase-1 (DPEP-1) in renal inflammation and chronic kidney disease (CKD).

Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced financial results for the second quarter of fiscal 2023, which ended December 31, 2022.